Iscalimab Biosimilar - Research Grade

Human

CD40

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse CD40 (FGK4.5) In Vivo Antibody - Low Endotoxin (ICH1073), Bulk Anti-Human CD40 (G28.5) Antibody (ICH1156), Dacetuzumab Biosimilar - Research Grade (ICH5030), Sotigalimab Biosimilar - Research Grade (ICH5031), Selicrelumab Biosimilar - Research Grade (ICH5032), Lucatumumab Biosimilar - Research Grade (ICH5129), Abiprubart Biosimilar - Research Grade (ICH5323), Bleselumab Biosimilar - Research Grade (ICH5407), Cifurtilimab Biosimilar - Research Grade (ICH5437), Dalnicastobart Biosimilar - Research Grade (ICH5462), Giloralimab Biosimilar - Research Grade (ICH5571), Mitazalimab Biosimilar - Research Grade (ICH5689), Ravagalimab Biosimilar - Research Grade (ICH5806), Teneliximab Biosimilar - Research Grade (ICH5915)

https://www.imgt.org/mAb-DB/

ICH3002

P25942

Blue ice

This product is a research-grade, unconjugated recombinant analog of iscalimab, an anti-CD40 antibody, supplied strictly for research use only and not for human or veterinary use. It is a human IgG1-kappa built around the CD40 target (UniProt P25942) to reproduce the binding specificity of the originator molecule while being manufactured to research specifications rather than as a therapeutic. The format is a non-therapeutic biosimilar intended as a functional tool: a defined, reproducible reagent for studying CD40 engagement and blockade in vitro and in preclinical settings. It is useful as a positive or isotype-matched control in binding and blocking assays, as a benchmarking standard when characterising new anti-CD40 candidates, and as a starting reagent for ADCC or ADC development workflows. Because iscalimab is engineered as a non-depleting, pathway-blocking antibody, the analog is well suited to experiments probing CD40-CD40L signalling interruption. It is available at low endotoxin (research grade typically under 1 EU/mg, with ultra-low options under 0.5 EU/mg) and in bulk milligram-to-gram quantities to support scale-up and repeated experiments. CD40 (UniProt P25942) is a type I transmembrane glycoprotein of the tumour necrosis factor receptor superfamily (TNFRSF5). It is expressed on antigen-presenting cells including B cells, dendritic cells, macrophages and monocytes, as well as on endothelial and epithelial cells and many tumours. Its ligand is CD40L (CD154), presented largely by activated CD4-positive T cells. CD40-CD40L engagement drives trimerisation of the receptor and recruitment of TRAF adaptor proteins, activating NF-kappaB, MAPK and other pathways. Functionally this delivers key costimulation: B-cell activation, germinal-centre formation, immunoglobulin class switching and affinity maturation, dendritic-cell licensing, and macrophage activation. Because the axis is central to T-cell-dependent humoral immunity and to sustaining inflammatory and autoimmune responses, CD40 is a prominent target for pathway-blocking approaches in transplantation and autoimmunity, which is the biology iscalimab is designed to interrupt.

CD40, Bp50, CDW40, TNFRSF5, p50, CD40 (protein), CD40 molecule

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks